Inactive Instrument

Press Releases EntreMed Inc Nasdaq

Equities

US29382F2020

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Mar. 28	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 05	Top Midday Gainers	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS	Apr. 08	PR
CASI Pharmaceuticals : Received Emergency Relief in connection with the Dispute with Juventas - Form 6-K	Apr. 08	PU
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS	Mar. 28	PR
CASI Pharmaceuticals : Received Notice of Termination of Commercialization Collaboration for CNCT19 from Juventas - Form 6-K	Mar. 13	PU
BioInvent International, CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed, Refractory Indolent Non-Hodgkin's Lymphoma In China	Mar. 06	AQ
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China	Mar. 05	AQ
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China	Mar. 05	PR
CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA	Feb. 16	PR
CASI Pharmaceuticals : Enters into Certain Agreements with respect to CASI Wuxi’s Reduction in Registered Capital and Convertible Loan - Form 6-K	Dec. 15	PU
CASI Pharmaceuticals : Enters into an Exclusive Distribution Agreement - Form 6-K	Dec. 08	PU
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES	Nov. 14	PR
CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA	Nov. 08	PR
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES	23-08-11	PR
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN in China to CASI Pharmaceuticals	23-08-02	AQ
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals	23-08-01	PR
CASI Pharmaceuticals : Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals	23-07-27	PU
CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339	23-07-20	PR
CASI Pharmaceuticals \| CASI Pharmaceuticals Announces First Quarter 2023 Financial Results	23-05-18	AQ
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS	23-05-17	PR
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022	23-04-26	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases EntreMed Inc Nasdaq

Equities

US29382F2020

Press Releases

Filters